IR@PKUHSC  > 北京大学公共卫生学院
学科主题公共卫生
Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China
Shang, Penghui1; Xia, Yinyin2; Liu, Feiying3; Wang, Xiaomeng4; Yuan, Yanli5; Hu, Daiyu6; Tu, Dehua7; Chen, Yixin8; Deng, Peiyuan8; Cheng, Shiming2; Zhou, Lin2; Ma, Yu9; Zhu, Lizhen9; Gao, Weiwei9; Wang, Hongyuan1; Chen, Dafang1; Yang, Li1; He, Pingping1; Wu, Shanshan1; Tang, Shaowen1; Lv, Xiaozhen1; Shu, Zheng1; Zhang, Yuan1; Yang, Zhirong1; Chen, Yan10; Li, Na11; Sun, Feng1; Li, Xiaoting12; He, Yingjian12; Garner, Paul13; Zhan, Siyan1
刊名PLOS ONE
2011-07-05
DOI10.1371/journal.pone.0021836
6期:7
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Multidisciplinary Sciences
研究领域[WOS]Science & Technology - Other Topics
关键词[WOS]INDUCED HEPATOTOXICITY ; INDUCED HEPATITIS ; TUBERCULOSIS ; PYRAZINAMIDE ; SUSCEPTIBILITY ; THERAPY
英文摘要

Background: Anti-tuberculosis drug induced liver injury (ATLI) is emerging as a significant threat to tuberculosis control in China, though limited data is available about the burden of ATLI at population level. This study aimed to estimate the incidence of ATLI, to better understand its clinical features, and to evaluate its impact on anti-tuberculosis (TB) treatment in China.

Methodology/Principal Findings: In a population-based prospective study, we monitored 4,304 TB patients receiving directly observed treatment strategy (DOTS) treatment, and found that 106 patients developed ATLI with a cumulative incidence of 2.55% (95% Confidence Interval [CI], 2.04%-3.06%). Nausea, vomiting and anorexia were the top three most frequently observed symptoms. There were 35 (33.02%) ATLI patients with no symptoms, including 8 with severe hepatotoxicity. Regarding the prognosis of ATLI, 84 cases (79.25%) recovered, 18 (16.98%) improved, 2 (1.89%) failed to respond to the treatment with continued elevation of serum alanine aminotransferase, and 2 (1.89%) died as result of ATLI. Of all the ATLI cases, 74 (69.81%) cases changed their anti-TB treatment, including 4 (3.77%) cases with medication administration change, 21 (19.81%) cases with drugs replacement, 54 (50.94%) cases with therapy interruption, and 12 (11.32%) cases who discontinued therapy. In terms of treatment outcomes, 53 (51.46%) cases had TB cured in time, 48 (46.60%) cases had therapy prolonged, and 2 (1.94%) cases died. Compared with non-ATLI patients, ATLI patients had a 9.25-fold (95% CI, 5.69-15.05) risk of unsuccessful anti-TB treatment outcomes and a 2.11-fold (95% CI, 1.23-3.60) risk of prolonged intensive treatment phase.

Conclusions/Significance: ATLI could considerably impact the outcomes of anti-TB treatment. Given the incidence of ATLI and the size of TB population in China, the negative impact is substantial. Therefore, more research and efforts are warranted in order to enhance the diagnosis and the prevention of ATLI.

语种英语
WOS记录号WOS:000292512000027
项目编号NO:TB07-030
资助机构China Program for the Global Fund
引用统计
被引频次:35[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54574
专题北京大学公共卫生学院
北京大学基础医学院
北京大学公共卫生学院_流行病与卫生统计学系
北京大学公共卫生学院_公共卫生学院
作者单位1.Peking Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100871, Peoples R China
2.Chinese Ctr Dis Control & Prevent, Ctr TB Control & Prevent, Beijing, Peoples R China
3.Ctr Dis Control & Prevent Guangxi Zhuang Autonomo, Nanning, Peoples R China
4.Ctr Dis Control & Prevent Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China
5.Ctr Dis Control & Prevent Jilin Prov, Changchun, Peoples R China
6.Ctr Dis Control & Prevent Chongqing Municipal, Chongqing, Peoples R China
7.Beijing Inst TB Control, Beijing, Peoples R China
8.State Food & Drug Adm, Ctr Drug Reassessment, Beijing, Peoples R China
9.Beijing TB & Thorac Tumor Res Inst, Beijing, Peoples R China
10.Indiana Univ, Sch Med, Dept Publ Hlth, Indianapolis, IN USA
11.Ctr Dis Control & Prevent Fangshan Dist, Beijing, Peoples R China
12.Beijing Inst Canc Res, Beijing, Peoples R China
13.Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Grp, Liverpool L3 5QA, Merseyside, England
推荐引用方式
GB/T 7714
Shang, Penghui,Xia, Yinyin,Liu, Feiying,et al. Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China[J]. PLOS ONE,2011,6(7).
APA Shang, Penghui.,Xia, Yinyin.,Liu, Feiying.,Wang, Xiaomeng.,Yuan, Yanli.,...&Zhan, Siyan.(2011).Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China.PLOS ONE,6(7).
MLA Shang, Penghui,et al."Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China".PLOS ONE 6.7(2011).
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Incidence, Clinical (91KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Shang, Penghui]的文章
[Xia, Yinyin]的文章
[Liu, Feiying]的文章
百度学术
百度学术中相似的文章
[Shang, Penghui]的文章
[Xia, Yinyin]的文章
[Liu, Feiying]的文章
必应学术
必应学术中相似的文章
[Shang, Penghui]的文章
[Xia, Yinyin]的文章
[Liu, Feiying]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。